AZ
спасибо большое, правда для этгго твиттер пришлось завести)))
на это и был расчет) интеграция в академический твиттер - одна из целей)
Size: a a a
2020 November 18
LD
на это и был расчет) интеграция в академический твиттер - одна из целей)
ну я вот до этого момента им пренебрегал))
ИК
ну это традиционный срач имхо не имеющий ответа. Но участие в жюри и комментирование механизма действия гипношпица - это странно, конечно
Я вот такое отношение воспринимаю, как перебирание жемчуга. Не надо поддерживать мутные движения, можно и нужно критиковать то, что не нравится, но вешать на человека ярлык лжеученого из-за того, что он как-то где-то подзашкварился – какой-то максимализм
E
ну это традиционный срач имхо не имеющий ответа. Но участие в жюри и комментирование механизма действия гипношпица - это странно, конечно
Про вопрос "ученый/руководитель" согласна, да. Можно быть и хорошим руководителем, и хорошим ученым при этом, противоречия как такового нет. Под "быть ученым" на высокой ступени я имела в виду скорее "не отрываться далеко от научной деятельности"
DP
Я вот такое отношение воспринимаю, как перебирание жемчуга. Не надо поддерживать мутные движения, можно и нужно критиковать то, что не нравится, но вешать на человека ярлык лжеученого из-за того, что он как-то где-то подзашкварился – какой-то максимализм
ну конкретно с Ключаревым я согласен, тем более тут именно текст. Переврать можно. Да и не большая проблема
Дубынин жи нет, он конкретно людям втирает хрень, причем, за деньги
Дубынин жи нет, он конкретно людям втирает хрень, причем, за деньги
ИК
ну конкретно с Ключаревым я согласен, тем более тут именно текст. Переврать можно. Да и не большая проблема
Дубынин жи нет, он конкретно людям втирает хрень, причем, за деньги
Дубынин жи нет, он конкретно людям втирает хрень, причем, за деньги
Ну хорошо, согласен
Но лучше лекций по медиаторным системам на русском все равно нет)
Но лучше лекций по медиаторным системам на русском все равно нет)
DP
Ну хорошо, согласен
Но лучше лекций по медиаторным системам на русском все равно нет)
Но лучше лекций по медиаторным системам на русском все равно нет)
Не спорю
M
А где Ключарев, там и Осадчий с Лебедевым. А Анохин крепко дружит с Черниговской - нет у нас, короче нейронауки незашкваренной, да?)))
+, смотреть можно
У него на фоне резонного изложения пара любимых тем (казоморфины в т ч), у той же Черниговской сплошной инсайт порн
У него на фоне резонного изложения пара любимых тем (казоморфины в т ч), у той же Черниговской сплошной инсайт порн
DK
у моего завлаба открылась позиция постдока (Прага):
BIOCEV – Havranek Lab https://havranek-lab.lf1.cuni.cz/about-us
Projects
The standard treatment of non-Hodgkin lymphomas (NHL) is still based on a non-specific and highly toxic chemotherapy combinations over 40 years old. Therefore, there is a great need for better understanding of lymphoma tumorigenesis to develop more specific therapies. We are currently working on a spectrum of projects in basic lymphoma biology with aim to provide such better targets for lymphoma treatment. Examples of our lymphoma research projects are:
Molecular details of B-cell receptor signal initiation and its transmission to protein kinase B.
Identification of biomarkers for personalized use of B-cell receptor signaling inhibitors.
Description of the role of lymphoma specific genomic alterations of novel epigenetic regulators.
Mechanisms of oncogenic PI3K/AKT pathway activation
Tumor specific crosstalk between signaling, metabolism and cell cycle.
Specifics of tumor metabolism.
Circulating tumor DNA as a diagnostic and therapy prediction tool.
We are looking for an enthusiastic candidate who is interested in basic and translational tumor biology research and is willing to learn a wide spectrum of advanced research methods.
We offer position in a young and dynamic research group with established international collaborations working within the state of the art BIOCEV institute with its exceptional core resources and equipment.
Position is available starting January 2021 (or earlier if preferred) with competitive salary based on performance and one-year extendable contract.
Contact
Applicants are encouraged to provide a short CV in English to ondrej.havranek@lf1.cuni.cz
BIOCEV – Havranek Lab https://havranek-lab.lf1.cuni.cz/about-us
Projects
The standard treatment of non-Hodgkin lymphomas (NHL) is still based on a non-specific and highly toxic chemotherapy combinations over 40 years old. Therefore, there is a great need for better understanding of lymphoma tumorigenesis to develop more specific therapies. We are currently working on a spectrum of projects in basic lymphoma biology with aim to provide such better targets for lymphoma treatment. Examples of our lymphoma research projects are:
Molecular details of B-cell receptor signal initiation and its transmission to protein kinase B.
Identification of biomarkers for personalized use of B-cell receptor signaling inhibitors.
Description of the role of lymphoma specific genomic alterations of novel epigenetic regulators.
Mechanisms of oncogenic PI3K/AKT pathway activation
Tumor specific crosstalk between signaling, metabolism and cell cycle.
Specifics of tumor metabolism.
Circulating tumor DNA as a diagnostic and therapy prediction tool.
We are looking for an enthusiastic candidate who is interested in basic and translational tumor biology research and is willing to learn a wide spectrum of advanced research methods.
We offer position in a young and dynamic research group with established international collaborations working within the state of the art BIOCEV institute with its exceptional core resources and equipment.
Position is available starting January 2021 (or earlier if preferred) with competitive salary based on performance and one-year extendable contract.
Contact
Applicants are encouraged to provide a short CV in English to ondrej.havranek@lf1.cuni.cz
T
у моего завлаба открылась позиция постдока (Прага):
BIOCEV – Havranek Lab https://havranek-lab.lf1.cuni.cz/about-us
Projects
The standard treatment of non-Hodgkin lymphomas (NHL) is still based on a non-specific and highly toxic chemotherapy combinations over 40 years old. Therefore, there is a great need for better understanding of lymphoma tumorigenesis to develop more specific therapies. We are currently working on a spectrum of projects in basic lymphoma biology with aim to provide such better targets for lymphoma treatment. Examples of our lymphoma research projects are:
Molecular details of B-cell receptor signal initiation and its transmission to protein kinase B.
Identification of biomarkers for personalized use of B-cell receptor signaling inhibitors.
Description of the role of lymphoma specific genomic alterations of novel epigenetic regulators.
Mechanisms of oncogenic PI3K/AKT pathway activation
Tumor specific crosstalk between signaling, metabolism and cell cycle.
Specifics of tumor metabolism.
Circulating tumor DNA as a diagnostic and therapy prediction tool.
We are looking for an enthusiastic candidate who is interested in basic and translational tumor biology research and is willing to learn a wide spectrum of advanced research methods.
We offer position in a young and dynamic research group with established international collaborations working within the state of the art BIOCEV institute with its exceptional core resources and equipment.
Position is available starting January 2021 (or earlier if preferred) with competitive salary based on performance and one-year extendable contract.
Contact
Applicants are encouraged to provide a short CV in English to ondrej.havranek@lf1.cuni.cz
BIOCEV – Havranek Lab https://havranek-lab.lf1.cuni.cz/about-us
Projects
The standard treatment of non-Hodgkin lymphomas (NHL) is still based on a non-specific and highly toxic chemotherapy combinations over 40 years old. Therefore, there is a great need for better understanding of lymphoma tumorigenesis to develop more specific therapies. We are currently working on a spectrum of projects in basic lymphoma biology with aim to provide such better targets for lymphoma treatment. Examples of our lymphoma research projects are:
Molecular details of B-cell receptor signal initiation and its transmission to protein kinase B.
Identification of biomarkers for personalized use of B-cell receptor signaling inhibitors.
Description of the role of lymphoma specific genomic alterations of novel epigenetic regulators.
Mechanisms of oncogenic PI3K/AKT pathway activation
Tumor specific crosstalk between signaling, metabolism and cell cycle.
Specifics of tumor metabolism.
Circulating tumor DNA as a diagnostic and therapy prediction tool.
We are looking for an enthusiastic candidate who is interested in basic and translational tumor biology research and is willing to learn a wide spectrum of advanced research methods.
We offer position in a young and dynamic research group with established international collaborations working within the state of the art BIOCEV institute with its exceptional core resources and equipment.
Position is available starting January 2021 (or earlier if preferred) with competitive salary based on performance and one-year extendable contract.
Contact
Applicants are encouraged to provide a short CV in English to ondrej.havranek@lf1.cuni.cz
спасибо
KL
у моего завлаба открылась позиция постдока (Прага):
BIOCEV – Havranek Lab https://havranek-lab.lf1.cuni.cz/about-us
Projects
The standard treatment of non-Hodgkin lymphomas (NHL) is still based on a non-specific and highly toxic chemotherapy combinations over 40 years old. Therefore, there is a great need for better understanding of lymphoma tumorigenesis to develop more specific therapies. We are currently working on a spectrum of projects in basic lymphoma biology with aim to provide such better targets for lymphoma treatment. Examples of our lymphoma research projects are:
Molecular details of B-cell receptor signal initiation and its transmission to protein kinase B.
Identification of biomarkers for personalized use of B-cell receptor signaling inhibitors.
Description of the role of lymphoma specific genomic alterations of novel epigenetic regulators.
Mechanisms of oncogenic PI3K/AKT pathway activation
Tumor specific crosstalk between signaling, metabolism and cell cycle.
Specifics of tumor metabolism.
Circulating tumor DNA as a diagnostic and therapy prediction tool.
We are looking for an enthusiastic candidate who is interested in basic and translational tumor biology research and is willing to learn a wide spectrum of advanced research methods.
We offer position in a young and dynamic research group with established international collaborations working within the state of the art BIOCEV institute with its exceptional core resources and equipment.
Position is available starting January 2021 (or earlier if preferred) with competitive salary based on performance and one-year extendable contract.
Contact
Applicants are encouraged to provide a short CV in English to ondrej.havranek@lf1.cuni.cz
BIOCEV – Havranek Lab https://havranek-lab.lf1.cuni.cz/about-us
Projects
The standard treatment of non-Hodgkin lymphomas (NHL) is still based on a non-specific and highly toxic chemotherapy combinations over 40 years old. Therefore, there is a great need for better understanding of lymphoma tumorigenesis to develop more specific therapies. We are currently working on a spectrum of projects in basic lymphoma biology with aim to provide such better targets for lymphoma treatment. Examples of our lymphoma research projects are:
Molecular details of B-cell receptor signal initiation and its transmission to protein kinase B.
Identification of biomarkers for personalized use of B-cell receptor signaling inhibitors.
Description of the role of lymphoma specific genomic alterations of novel epigenetic regulators.
Mechanisms of oncogenic PI3K/AKT pathway activation
Tumor specific crosstalk between signaling, metabolism and cell cycle.
Specifics of tumor metabolism.
Circulating tumor DNA as a diagnostic and therapy prediction tool.
We are looking for an enthusiastic candidate who is interested in basic and translational tumor biology research and is willing to learn a wide spectrum of advanced research methods.
We offer position in a young and dynamic research group with established international collaborations working within the state of the art BIOCEV institute with its exceptional core resources and equipment.
Position is available starting January 2021 (or earlier if preferred) with competitive salary based on performance and one-year extendable contract.
Contact
Applicants are encouraged to provide a short CV in English to ondrej.havranek@lf1.cuni.cz
Прикольно
KL
И че вы там, новые BTK и PI3K ингибиторы крафтите?
DK
Kirill Lepik
И че вы там, новые BTK и PI3K ингибиторы крафтите?
тестируем; можем и скрафтить при необходимости, но основная масса работы это молекулярное клонирование и трансфекция модельных линий
KL
А при каких видах лимфом
2020 November 19
D
Почему если мне снится число больше 4 знаков и я его во сне пытаюсь повторить несколько раз, в нем цыфры по одной- две при каждом повторе заменяются на случайные?
Н(
Может, это был кошмар?
MS
Ох ты какой вброс из Эмиратов позавчера был https://www.nature.com/articles/s41467-020-19723-8
MS
А твиттер только щас бомбануло, ReEeEeEEE :)
P
Здравствуйте, подскажите пожалуйста сколько обычно ученый получает за статью под грант (очень нужно знать) ?
PD
Нисколько